江湖电竞投注
DXCM
US
$
-0.28
-0.32%
Premarket
$
88.09
Before Hours Volume:
141
| Close | Chg | Chg % |
|---|---|---|
| $88.37 | 6.34 | 7.73% |
Volume: 2.82M
65 Day Avg: 2.82M
82.11
Day Range
88.60
66.89
52 Week Range
164.86
Overview
DXCM Overview
Key Data
- Open $82.56
- Day Range 82.11 - 88.60
- 52 Week Range 66.89 - 164.86
- Market Cap $32.2B
- Shares Outstanding 392.58M
- Public Float 387.85M
- Beta 1.05
- Rev. per Employee $424.35K
- P/E Ratio 182.43
- EPS $0.48
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 13.39M 08/15/22
- % of Float Shorted 3.45%
- Average Volume 2.82M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
19
Full Ratings
Recent News
DexCom stock drops 17% after company's Q2 miss
DexCom Inc. shares fell nearly 17% in the extended session Thursday after the maker of glucose monitoring systems missed analyst expectations for its first quarter and tweaked higher its 2022 revenue outlook. DexCom said ...
DexCom stock leads S&P 500's premarket gainers after denying merger talks, and Insulet stock drops
Shares of DexCom Inc. surged 8.1% to pace the S&P 500's premarket gainers, after the diabetes care company said it was not currently in "active discussions" regarding a merger. The stock has been dragged down over the pa...
Biotech and Pharma Insulet Stock Rises on Report of DexCom Acquisition Talks
Insulet's stock is up on Bloomberg report that it may be acquired by Dexcom
Shares of Insulet Corp. gained 9.9% in premarket trading on Tuesday, the day after that the company is in talks to be acquired by Dexcom Inc. , citing anonymous sources. Dexcom's stock was down 7.1% before the market ope...
DexCom stock price target cut to $555 from $630 at Stifel Nicolaus
Biotech and Pharma Insulet Stock Rises as It Joins the Automated Insulin Device Competition
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
In the latest trading session, DexCom (DXCM) closed at $82, marking a -1.3% move from the previous day.
on Zacks.com
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
on Zacks.com
10 Health Care Stocks Whale Activity In Today's Session
on Benzinga.com
Scissortail Wealth Management, LLC Cuts Portfolio Down to Size in 2nd Quarter
Scissortail Wealth Management, LLC Cuts Portfolio Down to Size in 2nd Quarter
on GuruFocus.com
GOLDMAN SACHS GROUP INC Buys 4, Sells 1 in 2nd Quarter
GOLDMAN SACHS GROUP INC Buys 4, Sells 1 in 2nd Quarter
on GuruFocus.com
Top 5 2nd Quarter Trades of DeepCurrents Investment Group LLC
Top 5 2nd Quarter Trades of DeepCurrents Investment Group LLC
on GuruFocus.com
Quantinno Capital Management LP Buys 4, Sells 1 in 2nd Quarter
Quantinno Capital Management LP Buys 4, Sells 1 in 2nd Quarter
on GuruFocus.com
3 Reasons to Buy the Dip With DexCom Stock
on Motley Fool
This Stock-Split Stock Is Up 30% Since Splitting Its Shares
on Motley Fool
Looking Into DexCom's Return On Capital Employed
on Benzinga.com
Why Is Senseonics (SENS) Stock Heating Up Today?
on InvestorPlace.com
2 Growth Stocks That Just Hit Setbacks: Are They Buys?
on Motley Fool
Where DexCom Stands With Analysts
on Benzinga.com
Raymond James Thinks Dexcom’s Stock is Going to Recover
Raymond James analyst Jayson Bedford maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $101.00. The company's shares closed last Friday at $82.08, close to its 52-week low of $66.89...
on TipRanks.com
Why DexCom Stock Is Falling Today
on Motley Fool
DexCom Inc.
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Abbott Laboratories |
|
$179.87B |
| Insulet Corp. |
|
$17.34B |
| Senseonics Holdings Inc. |
|
$702.83M |
| Provention Bio Inc. |
|
$369.42M |